title: Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives.
abstract: OBJECTIVE
  The Hypertension High Risk Management trial (HYRIM) investigated the effect of fluvastatin treatment and lifestyle intervention on development of carotid intima-media thickness (IMT) in drug-treated hypertensive patients.
  
  
  RESULTS
  HYRIM was a placebo-controlled, 2 x 2 factorial trial in which 568 drug-treated hypertensive men aged 40-74 years with total cholesterol 4.5-8.0 mmol/L, triglycerides <4.5 mmol/L, body mass index 25-35 kg/m2, and a sedentary lifestyle were randomized to receive either fluvastatin, 40 mg daily, or placebo, and either intensive lifestyle intervention (physical activity and diet) or usual care (treatment of hypertension and other disorders by own private physician). Carotid IMT was assessed by B-mode ultrasound vasculography and left ventricular (LV) mass was calculated from ultrasound recordings of the heart. Fluvastatin alone reduced the primary study endpoint of 4-year development of IMT in the common carotid artery (CCA) compared with placebo (p=0.0297). Carotid bulb IMT progression over 4 years was also significantly (p=0.0214) reduced by fluvastatin compared with placebo. Fluvastatin significantly lowered LDL-C levels (mean net difference through 4 years, 0.6 mmol/L; p<0.0001), and reduced the 2-year development of LV mass (p=0.0144) compared with placebo. Lifestyle intervention had no significant effect on LDL-C, carotid IMT or LV mass, and did not increase the effects of fluvastatin.
  
  
  CONCLUSIONS
  In drug-treated hypertensive patients in a usual care setting, fluvastatin treatment reduces progression of carotid IMT and LV mass.
authors.affiliation: Center for Preventive Medicine, Ullevål University Hospital, 0407 Oslo, Norway. sigmund.anderssen.nih.no
authors.forename: Sigmund A
authors.initials: SA
authors.lastname: Anderssen
authors.forename: Anne K
authors.initials: AK
authors.lastname: Hjelstuen
authors.forename: Ingvar
authors.initials: I
authors.lastname: Hjermann
authors.forename: Kirsti
authors.initials: K
authors.lastname: Bjerkan
authors.forename: Ingar
authors.initials: I
authors.lastname: Holme
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D004032:Diet; D015444:Exercise; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D000077340:Fluvastatin; D006352:Heart Ventricles / Q000033:anatomy & histology* / Q000473:pathology*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D008019:Life Style; D008297:Male; D008875:Middle Aged; D010919:Placebos; D017539:Tunica Intima / Q000033:anatomy & histology* / Q000473:pathology*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D010919:Placebos; D000077340:Fluvastatin